The recommendations come after the WHO's Strategic Advisory Group of Experts on immunisation held a meeting last week
Pfizer starts mid-stage trial for vaccine against omicron subvariant
The vaccine targets both the original as well as the BA.2 omicron subvariant
Published : 27 July 2022, 12:07 PM
Updated : 27 July 2022, 12:07 PM
Pfizer Inc and its German partner BioNTech SE said on Wednesday they had started a mid-stage study of a modified COVID-19 vaccine which targets both the original as well as the BA.2 omicron subvariant.
Pfizer said the vaccine is in an initial proof-of-concept study to gather more data.
Together, the BA.4 and BA.5 subvariants are estimated to make up nearly 95% of the circulating coronavirus variants in the United States for the week ended Jul 23.
RELATED STORIES
A second trial failure dealt a major blow to the French healthcare company's development prospects
The total number of suspected cases nationwide has jumped from 1,036 to 2,056 in four days and is largely prevalent among those who have not received vaccinations
Poxy McPoxface, TRUMP-22 or Mpox: these are some of the ideas sent in by the public to the World Health Organization as it seeks a new name for the disease
